[ Trevi Therapeutics raises $50.5M in Series C ]
Trevi Therapeutics has raised $50.5 million in Series C funding.
Founded in 2011, Trevi Therapeutics is a late-stage clinical development company focused on developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic and neuropathic conditions.
The Company plans to use the proceeds from the financing to advance the development of Nalbuphine® ER.
|City||Sandy Hook, Connecticut|
|Founder / CEO||Jennifer L. Good|
|Investors||New Enterprise Associates|
|Aperture Venture Partners|
|Previous Investors||Solar capital|
|Square 1 Bank|